CR Sanjiu completes TianShiLi asset acquisition

China Resources Sanjiu Medical & Pharmaceutical (CR Sanjiu) announced the completion of its significant asset purchase of TianShiLi Pharmaceutical Group on March 27, 2025. CR Sanjiu acquired 418,306,002 shares, representing 28% of TianShiLi's total issued share capital from TianShiLi Group and its concerted parties, making it the controlling shareholder. With the share transfer completed, TianShiLi becomes a subsidiary of CR Sanjiu, with China Resources Company, Limited taking over as TianShiLi's actual controller. The total consideration includes an initial intention payment of RMB 100 million and subsequent payments phased according to the agreement. This acquisition is seen as a strategic move for CR Sanjiu to expand its presence in the pharmaceutical sector.